Skip to content
Riskpilot
← Back to search
Sign in
Get full access
XELLIA PHARMACEUTICALS ApS
APS
Active
CVR 61094628
Dalslandsgade 11, 2300
København S
Manufacture of basic pharmaceutical products
·
NACE 2110
Est. 1959 · 67 years old
459 employees
Monitor
Share
Denmark
/
Companies
/
Manufacture of basic pharmaceutical products
/
XELLIA PHARMACEUTICALS ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
DKK millions
0M
645M
1B
2B
3B
1.8B
2021
2.2B
2022
2.0B
2023
1.6B
2024
1.5B
2025
EBITDA
DKK millions
5M
-207M
-418M
-630M
-841M
-550M
2021
-385M
+30%
2022
-673M
-75%
2023
-54M
+92%
2024
4M
+107%
2025
Income statement
DKK thousands
Item
2021
2022
2023
2024
2025
Revenue
1.792.626
2.245.303
1.986.816
1.599.382
1.461.516
Staff expenses
-215.744
-267.904
-490.630
-484.368
-0
EBITDA
-549.816
-385.457
-673.358
-54.465
3.935
Depreciation & amort.
649
-0
-0
-0
-0
EBIT
-550.465
-385.457
-673.358
-54.465
3.935
Net financials
-15.725
-97.579
-1.454.704
1.028.038
137.587
Profit before tax
-566.190
-488.370
-2.128.062
973.573
247.881
Tax
63.100
-116.884
256.839
144.607
34.143
Net profit
-503.090
-371.486
-2.384.901
828.966
213.738
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
2025
Total assets
3.733.699
3.460.247
2.105.002
3.200.468
2.829.479
Equity
2.082.735
1.750.675
-597.775
162.454
404.569
Long-term debt
679.750
559.586
538.260
568.539
474.424
Short-term debt
908.545
1.095.429
2.043.268
2.399.530
1.902.710
Total debt
1.588.295
1.655.015
2.581.528
2.968.069
2.377.134
Financial ratios
5-year trend
EBITDA margin
0.3%
This company
15.8%
Market median
-98% vs market
2021
2025
Equity ratio
14.3%
This company
38.2%
Market median
-63% vs market
2021
2025
Return on equity
52.8%
This company
18.4%
Market median
+187% vs market
2021
2025
Net profit margin
14.6%
This company
8.1%
Market median
+80% vs market
2021
2025
Asset turnover
0.52×
This company
1.12×
Market median
-54% vs market
2021
2025
Debt / equity
5.99×
This company
0.62×
Market median
-866% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on XELLIA PHARMACEUTICALS ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
